Abstract
One of the known risk factors for developing Alzheimer disease (AD) is hyperhomocysteinemia. The latter may result from mutations of the genes coding for three key enzymes involved in homocysteine metabolism (methylenetetrahydrofolate reductase [MTHFR], methionine synthase [MS], and cystathionine beta-synthase [CBS]). Although MTHFR and MS polymorphisms have been shown to be positively associated with AD in some populations, the relationship of the CBS gene with AD remains undefined. In order to evaluate whether AD is associated with CBS gene changes leading to decreased CBS activity and homocysteine accumulation, we genotyped the CBS 844ins68 mutation and VNTR polymorphisms of the CBS gene in 206 AD patients and 186 age-matched controls. A slight increase in both 844ins68 mutation and VNTR allele 19 frequencies was detected in the whole AD patient group, compared with controls. The division of AD patients and controls into three age-at-onset / age dependent subgroups ( < 65 years, 65-74 years, ≥ 75 years) revealed that the 844ins68 mutation and VNTR allele 19 are independent risk factors for AD development in subjects aged 75 years or more.
Keywords: alzheimer disease, cbs, 31 bp vntr, 844ins68 mutation, risk factors, age-at-onset/age
Current Alzheimer Research
Title: Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Volume: 1 Issue: 2
Author(s): Katrin Beyer, Jose I. Lao, Cristina Carrato, Ana Rodriguez-Vila, Pilar Latorre, Maria Mataro, Maria A. Llopis, Jose L. Mate and Aurelio Ariza
Affiliation:
Keywords: alzheimer disease, cbs, 31 bp vntr, 844ins68 mutation, risk factors, age-at-onset/age
Abstract: One of the known risk factors for developing Alzheimer disease (AD) is hyperhomocysteinemia. The latter may result from mutations of the genes coding for three key enzymes involved in homocysteine metabolism (methylenetetrahydrofolate reductase [MTHFR], methionine synthase [MS], and cystathionine beta-synthase [CBS]). Although MTHFR and MS polymorphisms have been shown to be positively associated with AD in some populations, the relationship of the CBS gene with AD remains undefined. In order to evaluate whether AD is associated with CBS gene changes leading to decreased CBS activity and homocysteine accumulation, we genotyped the CBS 844ins68 mutation and VNTR polymorphisms of the CBS gene in 206 AD patients and 186 age-matched controls. A slight increase in both 844ins68 mutation and VNTR allele 19 frequencies was detected in the whole AD patient group, compared with controls. The division of AD patients and controls into three age-at-onset / age dependent subgroups ( < 65 years, 65-74 years, ≥ 75 years) revealed that the 844ins68 mutation and VNTR allele 19 are independent risk factors for AD development in subjects aged 75 years or more.
Export Options
About this article
Cite this article as:
Beyer Katrin, Lao I. Jose, Carrato Cristina, Rodriguez-Vila Ana, Latorre Pilar, Mataro Maria, Llopis A. Maria, Mate L. Jose and Ariza Aurelio, Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease, Current Alzheimer Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567205043332243
DOI https://dx.doi.org/10.2174/1567205043332243 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology The Role of PPARs in Obesity and other Insulin Resistance Associated Disorders
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Chemistry of the Meliaceae and Ptaeroxylaceae of Southern and Eastern Africa and Madagascar
Current Organic Chemistry The Antidiabetic PPARγ Ligands: An Update on Compounds in Development
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Cardiac Repair: The Intricate Crosstalk between the Epicardium and the Myocardium
Current Stem Cell Research & Therapy COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Preparation and Biodistribution of Technetium-99m-Labeled Bis- Misonidazole (MISO) as an Imaging Agent for Tumour Hypoxia
Medicinal Chemistry Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets The Role of Hyphenated Chromatography-Mass Spectrometry Techniques in Exploratory Drug Metabolism and Pharmacokinetics
Current Pharmaceutical Design Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Knowing is Half the Battle: Targeting Virulence Factors of Group A Streptococcus for Vaccine and Therapeutics
Current Drug Targets Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews Strategies for Integral Metabolism Profile of Multiple Compounds in Herbal Medicines: Pharmacokinetics, Metabolites Characterization and Metabolic Interactions
Current Drug Metabolism